Cancer early detection: Strategies, barriers and solutions
Dr Ophira Ginsburg - NYU Langone Health, New York City, USA
Cancer early detection: Strategies, barriers and solutions ( Dr Ophira Ginsburg - NYU Langone Health, New York City, USA )
6 Nov 2019
Analysis of assay used in IMpassion130 to guide treatment of metastatic and adva...
Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia
Analysis of assay used in IMpassion130 to guide treatment of metastatic and advanced breast cancers ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )
31 Oct 2019
Treatment pathways for patients with triple-negative breast cancer
Elahe Salehi - Dana-Farber Cancer Institute, Boston, USA
Treatment pathways for patients with triple-negative breast cancer ( Elahe Salehi - Dana-Farber Cancer Institute, Boston, USA )
23 Oct 2019
PARP inhibitors in metastatic breast cancer: The present and the future
Elahe Salehi - Dana-Farber Cancer Institute, Boston, USA
PARP inhibitors in metastatic breast cancer: The present and the future ( Elahe Salehi - Dana-Farber Cancer Institute, Boston, USA )
23 Oct 2019
Shaping the future of metastasis - ecancer investigates
Monique Biryiana - ecancer Medical Reporter, Dr Chris Bakal - Dynamical Cell Sys...
Shaping the future of metastasis - ecancer investigates ( Monique Biryiana - ecancer Medical Reporter, Dr Chris Bakal - Dynamical Cell Systems Team Leader, Patricia Pascual Vargas - PhD Student )
14 Oct 2019
PARP inhibitors for metastatic breast cancer
Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany
PARP inhibitors for metastatic breast cancer ( Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany )
7 Oct 2019
KATHERINE trial updates for HER2-positive breast cancer
Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany
KATHERINE trial updates for HER2-positive breast cancer ( Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany )
7 Oct 2019
Highlights from ESMO 2019
Prof Josep Tabernero - ESMO President
Highlights from ESMO 2019 ( Prof Josep Tabernero - ESMO President )
4 Oct 2019
MEDIOLA: Olaparib and durvalumab for germline BRCA-mutated metastatic breast can...
Prof Susan Domchek - University of Pennsylvania, Pennsylvania, USA
MEDIOLA: Olaparib and durvalumab for germline BRCA-mutated metastatic breast cancer ( Prof Susan Domchek - University of Pennsylvania, Pennsylvania, USA )
4 Oct 2019
Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative ad...
Dr Véronique Diéras - Centre Eugène Marquis, Rennes, France
Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer ( Dr Véronique Diéras - Centre Eugène Marquis, Rennes, France )
4 Oct 2019
Using PARP inhibitors to improve quality of life for patients with metastatic br...
Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia
Using PARP inhibitors to improve quality of life for patients with metastatic breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )
3 Oct 2019
Breast cancer highlights from ESMO 2019
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
Breast cancer highlights from ESMO 2019 ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
2 Oct 2019